Acquiring patients is not the hard part anymore. Keeping them coming back for virtual visits instead of defaulting to in-person care is. Telemedicine growth requires a fundamentally different approach than standard SaaS – one that accounts for physician supply constraints, clinical quality metrics, and the regulatory friction that shapes every growth lever.

The Problem

Patient retention rates are declining across the industry

The initial surge of telemedicine adoption during 2020-2021 has normalized, and many patients have returned to in-person care. Retention rates for most telemedicine platforms sit well below what investors expect from SaaS businesses. The problem is not awareness – patients know telehealth exists. The problem is that most platforms have not given patients a compelling reason to choose virtual care for their next visit.

Physician supply constrains growth ceilings

You cannot scale patient volume without physician capacity. Most telemedicine companies treat physician recruitment as a hiring function rather than a growth function. When physician supply does not keep pace with patient demand, wait times increase, appointment availability drops, and patients leave. Your growth strategy has to solve the supply side, not just the demand side.

Unit economics deteriorate at scale without discipline

Patient acquisition costs in telemedicine are rising as competition increases and the easy-to-convert patients have already been acquired. Meanwhile, reimbursement rates are under pressure from payers pushing back on telehealth parity. Without clear focus on which patients, conditions, and channels deliver the best unit economics, growth spending produces revenue without margin.

Regulatory changes create growth strategy whiplash

Telemedicine regulations shift frequently – state licensing compacts, prescribing rules, and reimbursement policies all affect which markets you can serve and how. Companies that build growth strategies around regulatory assumptions find themselves replanning when policies change. Growth planning in telemedicine requires scenario-based thinking that most companies do not invest in.

How We Help

We build growth strategies that treat physician supply and patient demand as two halves of the same equation. Most telemedicine companies have separate teams working on physician recruitment and patient acquisition with no coordination between them. We create unified growth models that match supply development with demand generation by market, specialty, and time horizon.

Retention strategy gets as much attention as acquisition. We analyze patient drop-off points, visit completion patterns, and the clinical and UX factors that determine whether a patient books a second appointment. We develop re-engagement programs, clinical follow-up workflows, and patient experience improvements that compound retention over time rather than just adding more patients to a leaky bucket.

Unit economics discipline is built into every growth recommendation. We model CAC, LTV, and contribution margin by channel, condition, and market segment. This lets you make investment decisions based on which growth levers produce profitable scale, not just revenue growth. We also model regulatory scenarios so your growth plan has contingencies for policy changes.

We design growth experiments that test new channels, markets, and service lines with minimum investment before scaling. Each experiment has clear success criteria, measurement frameworks, and kill criteria. This prevents the common pattern of launching into new segments based on assumptions rather than data.

What we deliver

Unified growth model integrating physician supply and patient demand
Patient retention analysis and re-engagement strategy
Unit economics model by channel, condition, and market
Regulatory scenario planning for growth contingencies
Growth experiment framework with prioritized test roadmap

Telemedicine growth is a supply-side problem disguised as a demand-side problem. The companies that win are the ones that solve physician recruitment, retention, and scheduling before they pour money into patient acquisition.

Our Methodology

The first 30 days are spent understanding your growth engine. We analyze patient acquisition funnels, physician utilization rates, retention curves, and unit economics across every segment you serve. We interview your clinical, product, and growth teams to understand operational constraints. We also benchmark your metrics against industry patterns to identify where the biggest improvement opportunities exist.

Days 31-60 focus on strategy development. We build the unified growth model that connects physician supply planning with patient demand generation. We design retention programs, channel optimization strategies, and market expansion plans. We also develop the regulatory scenario models that protect your growth plan against policy changes. Everything is tied to specific financial outcomes so the board can evaluate trade-offs.

The final 30 days involve implementation planning and experiment design. We set up the growth experiment framework, define the first batch of tests, instrument measurement systems, and prepare your team to execute independently. You leave with a growth strategy that is both ambitious and operationally realistic, plus the testing infrastructure to keep improving it.

How We Work

We start with a two-week data deep-dive. We analyze your patient funnel, physician network metrics, financial data, and competitive positioning. We interview key stakeholders across growth, clinical, product, and finance. This produces the diagnostic that informs every strategic recommendation.

Our team pairs a healthcare growth strategist with a data analyst who specializes in marketplace metrics. From your side, we need access to your analytics platform, financial models, and the teams responsible for physician recruitment and patient acquisition. We operate on weekly strategy sessions with bi-weekly executive reviews.

Growth improvements typically begin appearing within 6-8 weeks as retention and channel optimizations take effect. Physician supply improvements show results within 8-12 weeks. New market expansions take 3-6 months to validate. Initial engagements run 3-4 months with ongoing growth advisory available for companies in active scaling phases.

Improved patient retention and visit frequency
Physician supply growth aligned with demand
Better unit economics and channel efficiency
Data-driven growth experimentation process

If your telemedicine company needs growth strategy leadership, we should talk.

Expand your marketing team output with our experts

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.

Frequently asked questions

How much does a growth strategy engagement cost for telemedicine companies?

Growth strategy engagements typically run $40K-60K for the 90-day sprint including data analysis, strategy development, and experiment design. Ongoing growth advisory ranges from $12K-20K per month. The engagement typically pays for itself through improved unit economics and reduced wasted spend within the first quarter. We focus investment on the channels and segments that actually drive profitable growth.

How do you improve patient retention in telemedicine?

We start by analyzing where patients drop off and why. Common drivers include poor first-visit experience, lack of follow-up, condition resolution, and friction in rebooking. We design interventions at each drop-off point – clinical follow-up workflows, re-engagement campaigns, UX improvements, and care continuity features. Retention improvement is incremental and compounds over time, which is why it matters more than acquisition for long-term growth.

What growth metrics matter most for telemedicine companies?

Beyond standard SaaS metrics, telemedicine companies should track visit completion rate, patient return rate by condition, physician utilization rate, supply-demand ratio by market, and CAC by acquisition channel. We also look at condition-specific LTV and geographic unit economics. These metrics tell you whether your growth is sustainable, not just whether your top line is moving.

How do you balance growth across DTC and B2B channels?

We model the unit economics and growth potential of each channel independently, then build a portfolio strategy that allocates investment based on stage-appropriate returns. DTC usually drives faster learning but higher CAC. B2B channels through employers and health systems deliver lower CAC at scale but take longer to develop. Most companies need both, but the sequencing and resource allocation between them matters significantly.

Can growth strategy help with fundraising for telemedicine companies?

Yes. Investors want to see clear growth levers, defensible unit economics, and a path to efficient scale. Our growth strategy deliverables include the financial models, market sizing, and channel economics that investors evaluate during diligence. Companies typically use the growth model and scenario analysis in board presentations and fundraising materials. A clear growth strategy with supporting data significantly strengthens your fundraising position.

How do regulatory changes affect telemedicine growth strategy?

We build regulatory scenarios into every growth plan. This means modeling what happens to your growth trajectory if specific policies change – interstate licensing compacts, prescribing regulations, reimbursement parity laws. Rather than building a strategy that depends on favorable regulation, we design plans that work under multiple regulatory outcomes. This gives you and your board confidence that growth is not dependent on a single policy assumption.